My concern is that in those early-onset type 2 patients, we know that they progress much more quickly, they have a much faster deteriorating beta cell function, and we simply don’t know whether remission of type 2 diabetes is the same and is as effective as it is in the older population. Hello, I’m Melanie Davies and I’m a Professor of Diabetes Medicine in Leicester in the UK and also a consultant diabetologist at University Hospitals of Leicester. So the five things that I think we don’t know yet, firstly, in terms of early-onset type 2 diabetes, so people developing diabetes under the age of 40: Virtually all of our evidence, whether it comes in terms of outcome trials looking at cardiorenal outcomes, whether it looks at studies of diet and exercise and self-management, or whether it looks at the phase III trials of many of the common therapies that we use routinely in the clinic are based on populations over the age of 40, whereas increasingly we are treating people under the age of 40. The second area also relates to early-onset type 2 diabetes. We hear a lot about remission and whether it’s possible to lead to remission in type 2 diabetes. And we’ve had some excellent data from the DiRECT study and from other information. But my concern is that in those early-onset type 2 patients, we know that they progress much more quickly, they have a much faster deteriorating beta cell function, and we simply don’t know whether remission of type 2 diabetes is the same and is as effective as it is in the older population. The third area is the use of some of the modern technology, for example, continuous glucose monitoring in people living with type 2 diabetes not on insulin. This has been hugely effective in type 1 diabetes. There’s reasonable evidence in people on insulin, but there’s a complete lack of evidence in people not on insulin therapy. And the reason I think this is important that we get this evidence is because we don’t know if it works in a similar way in type 1, which is very much around adjustment of insulin therapy. In type 2, there’s a whole series of other factors that could benefit type 2 diabetes but also could be an additional burden. The fourth area is how do we really tackle effectively stigma in people living with type 2 diabetes and obesity? It’s a huge problem. It really impacts on people’s lives. And I’m not sure that we have a good evidence base of interventions that could really address stigma in people living with type 2 diabetes. And the final area that I think is really important is that we’ve seen really rapid development and innovation in weight loss therapies, but we really don’t know how that impacts on physical function, on sarcopenia in people particularly with obesity, but also with type 2 diabetes and obesity. We know that in type 2 diabetes there’s accelerated ageing, poor physical function, even in people in their middle age. And yet we may be using very effective weight loss drugs that may reduce lean mass. We need to understand much more about that area.